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Previewssustains Trm. Depletion of cells expressing
CD11b+, a marker for macrophages, led
to a reduction in CD4+ (and CD8+) Trm as
did blockade of the chemokine CCL5.
Moreover, Iijima and Iwaski detected
CD4+ Trm that produce a low level of
IFN-g ex vivo without the need for restim-
ulation with peptide. They propose a
model where Trm-derived-IFN-g induces
local macrophages to produce CCL5,
which in turn prevents Trm from being
expulsed into the vaginal lumen (Figure 1).
Thus, Trm not only instruct innate immune
cells upon infection but keep instructing
them in order to maintain themselves at
the initial site of infection.
These three recent reports (Ariotti et al.,
2014; Iijima and Iwasaki, 2014; Schenkel
et al., 2014a) show the potential power
and precision Trm may provide to protect
against specific infections. In order to
translate these findings into effective vac-
cine strategies, we will need a more
comprehensive understanding of how to
maximize the number of Trm and to pro-
long their longevity in a specific tissue.
The complexity of Trm is substantial asCD4+ and CD8+ T cells behave differently
and the maintenance of Trm is very tissue
specific. For instance, it is unlikely that
expulsion into the lumen is a major
concern for skin Trm, whereas the large
surface area of the lung may require
active repression of Trm shedding into
the lung airways. On that note, the
longevity of Trm appears to greatly differ
between tissues as skin Trm are main-
tained in mice for over a year (Mackay
et al., 2012), whereas lung Trm may only
be detectable for a few months (Wu
et al., 2013). Despite these challenges,
vaccine-induced Trm could be worth the
effort, particularly in the case of patho-
gens such as HIV, where rapid induction
of an antiviral state by Trm could be pivotal
to prevent systemic dissemination.REFERENCES
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During its developmental transformation in the mammalian host, Trypanosma cruzi discards it flagellum into
the cytoplasm of the host cell. In the current issue of Cell Host & Microbe, Kurup and Tarleton (2014) exploit
the antigens made available by this process to develop a more effective vaccine strategy.The Kinetoplastid protozoan parasites
that include African trypanosomes, Trypa-
nosma cruzi, and various Leishmania sp.
produce a spectrum of human and veter-
inary diseases that continue to pose enor-
mous public health concerns throughout
tropical and subtropical regions. Impor-
tantly, there are no effective vaccines
against any of these vector-borne dis-
eases. A major impediment to vaccine
development is the complexity of the
antigens that these eukaryotic pathogens
offer as immunologic targets and theirremarkable adaptability to immunologic
pressure. Thus, the large genome sizes
and proteomes possessed by these para-
sites may preclude responses to anything
but a few immunodominant epitopes
encoded by genes that are driven to
display extensive allelic or somatic poly-
morphisms. In the current studies, Kurup
and Tarleton (2014) develop a strategy to
identify invariant, subdominant, and early
antigens targets that can be incorporated
into a live, attenuated vaccine to poten-
tiate a protective response.Trypanosma cruzi is the causative agent
of Chagas disease, which is the most
prevalent cause of infectious myocarditis
in Central and South America. The basic
life cycle of Trypanosma cruzi was
described by Carlos Chagas over one
century ago (Chagas, 1909) and is sum-
marized in Figure 1.Metacyclic trypomas-
tigotes are the flagellated, extracellular-
stage parasites that are excreted by an
infected reduviid bug. The excreta can
contaminate the bite wound or mucous
membranes, allowing the metacyclics to6, October 8, 2014 ª2014 Elsevier Inc. 423
Figure 1. Life Cycle of Trypanosoma cruzi
Trypanosoma cruzi has a biphasic life cycle in
which four developmental forms, epimastigotes
(A), metacyclic trypomastigotes (B), amastigotes
(C), and bloodstream trypomastigotes (D), alter-
nate between the insect vector and themammalian
host. Epimastigotes and amastigotes are the
replicative stages of the insect vector and mam-
malian host, respectively. Metacyclic and blood-
stream trypomastigotes provide the source of
the discarded flagellum and flagellar rod proteins
for CD8+ T cell priming and recognition during their
transformation to amastigotes in the cytoplasm of
the host cell. Modified from Perez et al. (2014).
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Previewsgain entry into themammalian host, where
they are able to infect a wide range of
nucleated cells. The trypomastigotes
rapidly escape the parasitophorous vacu-
ole and transform in the cytoplasm into the
amastigote stage, an ovoid form charac-
terized by a short flagellum that does not
extend beyond the flagellar pocket.
Amastigotes replicate in the cytoplasm
and give rise to bloodstream trypomasti-
gotes that escape into the blood and
invade new cells in a manner similar to
metacyclic invasion. Given their cyto-
plasmic residence and the fact that many
of the parasitized cells lack MHC class II
molecules, protective immunity against
T. cruzi infection is believed to be primarily
CD8+ T cell dependent (Padilla et al.,
2009). The natural CD8+ T cell response
to T. cruzi infection in both mice and hu-
mans seems to be focused on epitopes
encoded by genes of the large and
strain-variant trans-sialidase gene family,
which would require that a massive num-
ber of target epitopes be included in an
effective vaccine (Martin et al., 2006).424 Cell Host & Microbe 16, October 8, 2014In their search for strain-invariant epi-
topes that might elicit a protective
response, Kurup and Tarleton (2014)
reasoned that during the transformation
of trypomastigotes to amastigotes in
the host cell cytoplasm, the discarded
flagellum might be a source of immuno-
genic, class I-restricted peptides for early
CD8+ T cell priming. The unique availabil-
ity of catabolized flagellar proteins for
class I loading had been previously sug-
gested (Michailowsky et al., 2003).
Furthermore, it was already known that
immunization with proteins present in the
paraflagellar rod (PFR), which is the major
structural component of the T. cruzi
flagellum—and indeed all life stages
of Kinetoplastida with the exception of
amastigotes—confers protective immu-
nity against T. cruzi infection in mice
(Miller et al., 1997). The PFR is a lattice-
like arrangement of protein filaments
that in T. cruzi is composed of four major
proteins, PAR1–PAR4. By expressing a
tagged form of PAR4, Kurup and Tarleton
(2014) could directly visualize the loss and
degradation of the flagellum in the host
cell cytoplasm. This event was preceded
by an asymmetrical division of the trypo-
mastigote into two distinct daughter cells:
one, a nucleated cell with a short flagellum
that fully transforms into the first gene-
ration amastigote, and the other, an
anucleate cell with an intact kinetoplast
and elongate flagellum that disintegrates
9–12 hr postinfection, as visualized by
the appearance of minute tagged parti-
cles in the cytosol of the infected macro-
phages. In vivo, a PAR4-specific CD8+
T cell response could be detected in
T. cruzi-infected mice, and overexpres-
sion of PAR4 in the parasite enhanced
the PAR4-specific response during infec-
tion. Most importantly, mice that were
infected with the PAR4-overexpressing
parasites and then drug cured had stron-
ger protection against a challenge infec-
tion compared to mice drug cured of their
wild-type parasites. Kurup and Tarleton
(2014) also showed that the PARA4-
specific CD8+ T cells recognize the
cognate epitope very quickly on infected
cells, within a few hours after infection
of fibroblasts in vitro. By linking a trans-
sialidase epitope (TSKb20) to PARA4,
they could accelerate the TSKb20-spe-
cific response, providing further evidence
that flagellar degradation during stage
transformation is an exceptional sourceª2014 Elsevier Inc.of immunogenic peptides for early CD8+
T cell priming and activation. Kurup and
Tarleton (2014) argue that it is the rapid
kinetics of the anti-PAR4 response,
along with overexpression of the target
epitope, that allowed the subdominant
response to mediate stronger protection
as compared to the still dominant but
delayed response to the trans-sialidase
proteins. Overexpression of additional
PFR proteins—the PFR proteome con-
sists of at least 30 proteins (Portman
et al., 2009)—might further enhance the
efficacy of a live, attenuated T. cruzi
vaccine.
How applicablemight the potentiation of
early T cell responses to flagellar pro-
teins be to vaccination against other
Kinetoplastid parasites? Whereas African
trypanosomes retain anexclusive extracel-
lular lifestyle as trypomastigote forms in the
blood and tissues of their mammalian
hosts, Leishmania sp. undergo rapid trans-
formation to amastigotes following uptake
of the flagellated, metacyclic stage pro-
mastigotes by neutrophils and macro-
phages in the skin at the site of delivery
by sand fly bite. The impressive length of
the metacyclic flagellum may provide an
especially good source ofmaterial for early
priming and detection by the immune
response. As Leishmania do not escape
the phagosome, the antigens made avail-
able by the discarded flagellum might be
more relevant to CD4+ T cell responses,
though endosomal processing of Leish-
mania-derived antigens for class I presen-
tation has also been described (Bertholet
et al., 2006). Themorecritical cell biological
difference maybe that whereas reinvasion
of cells byT. cruzibloodstream trypomasti-
gotes will probably provide a continuous
source of flagellar proteins for boosting
and for presentation by infected cells, the
presentation of Leishmania flagellar pro-
teins will be confined to only the earliest
stage of infection by metacyclic promasti-
gotes. Nonetheless, immunization with
PFR-2 as a protein- and/or DNA-based
vaccine succeeded in producing smaller
lesions in hamsters challenged with
L. panamensis or L. mexicana, suggesting
that early T responses to even the most
fleeting of antigens can be protective
(Saravia et al., 2005).
It is not clear that the approach so care-
fully developed in this report will ever
achieve the sterilizing immunity that may
be required of a prophylactic vaccine
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Previewsfor human Chagas disease, in which
the myocarditis is associated with persis-
tent infection. Nonetheless, the studies
validate the selection of target antigens
that are invariant, subdominant, and
exposed early in the infectious cycle, as
a general strategy to undermine the
immune evasive capacity of vector borne
parasites.
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The intestinal microbial ecosystem is complex, and few of the principles that contribute to homeostasis in
health are well understood. Pham et al. (2014) show that a network including the epithelial interleukin-22
receptor protects against infection with the opportunistic pathogen Enterococcus faecalis through promo-
tion of host-microbiota mutualism.The human gastrointestinal (GI) tract is
a rich and highly complex ecosystem,
where a wide variety of bacterial, fungal,
and viral inhabitants coexist with one
other and in symbiosis with their host.
This diverse microbial community aids
digestion, synthesizes vitamins, and pro-
tects the host against infection. But the
microbiota exists in a delicate balance
that is periodically disrupted, resulting in
a state of microbial dysbiosis. The factors
that precipitate microbial dysbiosis, and
how to prevent or reverse it, are not well
understood.
Recent studies point to the complex
interplay between diet, community com-
plexity, and host immunity in maintaining
GI tract microbial homeostasis (Turn-
baugh et al., 2009; Jernberg et al., 2007;
Deatherage Kaiser et al., 2013). Not sur-
prisingly, diet is an important factor in
determining GI community composition.
When host diet shifts, the compositionof the GI microbial ecosystem also
shifts (Turnbaugh et al., 2009). Over the
past 50 years, antibiotic treatment has
emerged as an important cause of micro-
bial dysbiosis; broad-spectrum antimi-
crobials fundamentally change the
composition of GI tract flora, and the
effects can persist for years (Jernberg
et al., 2007). Infection with a virulent path-
ogen such as Salmonella can also alter
community structure and result in dysbio-
sis (Deatherage Kaiser et al., 2013).
Finally, the host immune system plays a
key role inmaintaining amicrobial homeo-
stasis compatible with health. The im-
mune system is ‘‘trained’’ as healthy flora
are established during development and
becomes capable of distinguishing be-
tween beneficial and harmful GI tract
microbes. When working properly, the
immune system is able to promote the
occurrence of the former and suppress
the latter. But when this training goesawry, or when host immunity is disrupted,
the GI tract ecosystem can tilt toward
dysbiosis and disease (Figure 1).
What are the key interactions between
the host immune system and the GI tract
microbial community that contribute to
or prevent dysbiosis? In this issue, Pham
and colleagues explore the role of the
interleukin-22 receptor IL-22RA1 in main-
taining microbial homeostasis in the
mouse GI tract (Pham et al., 2014).
Because intestinal inflammation can
cause dysbiosis, the authors hypothe-
sized that IL-22RA1 contributes to
maintaining microbial homeostasis by
restricting the overgrowth of opportu-
nistic pathogens. In a series of experi-
ments in mice lacking IL-22RA1, the
authors demonstrate that during micro-
bial dysbiosis, the opportunistic pathogen
Enterococcus faecalis is able to expand in
relative abundance in the intestinal tract
and then translocate to the bloodstream6, October 8, 2014 ª2014 Elsevier Inc. 425
